Additional Expertise Amid Growing Concerns about the Safety of Illicit Cannabis Products



SAN FRANCISCO, Calif—September 25, 2019—PAX Labs, Inc., a leading consumer technology brand in cannabis, today announced the formation of a health advisory board. Composed of highly respected experts across immunology, cannabis research and patient safety, this board underscores PAX’s commitment to consumer health. The board will meet quarterly and advise on key areas including vaporization safety, mental health and medical applications for PAX products.

“Amid growing concern about the risks—and prevalence—of illicit cannabis, our top priority at PAX remains consumer safety,” said PAX President and CEO Lisa Sergi. “The formation of this board has been in the works for some time. It’s an obvious next step for PAX as we blend our industry-leading innovation with continuous research in cannabis and vapor technology.”

“Our customers expect us to make wise choices regarding their health and safety, and we take that responsibility very seriously,” said Conrad Legendy, Director of Applied Research at PAX. “We look forward to drawing on our health advisory board’s expertise and thought leadership as we continue to develop category-defining products.”

“I’ve pursued my passion for cannabis product safety for over a decade and look forward to continuing that work through this role with PAX,” said Dr. Jahan Marcu, Co-founder of the International Research Center on Cannabis and Health. “The formation of this board speaks volumes to PAX’s commitment to prioritizing the best interests of consumers and patients.”

Background on Health Advisory Board Members

Dr. Anne Maitland, M.D., Ph.D. is a thought leader on immune-mediated disorders and the emerging field of Mast Cell disorders. She currently serves as an Assistant Professor at Mount Sinai Hospital in New York and a Medical Director of Comprehensive Allergy & Asthma Care in Westchester. She is on advisory boards for The Ehlers Danlos Society, The Mastocytosis Society, Dysautonomia International, and the Chiari Syringomelia Foundation.

Dr. Arno Hazekamp, Ph.D. is an acclaimed cannabis researcher and leader in vaporization science. He has been involved in the Dutch medicinal cannabis program since its inception, specializing in quality control, product development and clinical trial design, and is the former Head of Research and Education at Bedrocan BV—the Netherlands’ official medicinal cannabis grower. He is an active lecturer and advocate, and creator of the Medicinal Cannabis Masterclass.

Dr. Douglas Melancon, M.D. is Co-research Director and oversees healthcare investments at Advent Capital Management. Dr. Melancon has deep expertise analyzing and distilling complex medical and pharmaceutical research, and has a strong understanding of the FDA and navigating the complex regulatory environment. He previously served as a Portfolio Manager at Merlin Biomed and a Biotechnology Analyst at Morgan Stanley and Merrill Lynch.

Dr. Jahan Marcu, Ph.D. has over 15 years of experience in cannabis research, policy, and operations. He is the Chief Science Officer and Co-founder of the International Research Center on Cannabis and Mental Health and was previously the Chief Science Officer at Americans for Safe Access. He serves on multiple advisory committees and is among a select group of professionals globally with a Ph.D. focused on the endocannabinoid system.

About PAX Labs

PAX is a leader in the design and development of premium app-controlled vaporization technologies and devices. Headquartered in San Francisco, PAX has revolutionized the consumer experience through innovation and product design and is committed to taking the guesswork out of cannabis with products that offer quality, transparency, and predictability. PAX has sold more than 500,000 Era devices for oil concentrates and over one million devices in the flower vaporizer category. PAX is committed to its mission: establishing cannabis as a force for good. PAX Labs does not manufacture, produce or sell cannabis. pax.com

Contact

press@pax.com